Overview

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Status:
Completed
Trial end date:
2020-08-05
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.
Phase:
Phase 2
Details
Lead Sponsor:
Aptinyx
Collaborators:
Massachusetts General Hospital
Premier Research Group plc